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Castleman’s Disease in the Head and Neck Region:
Meta-analysis of Reported Cases in Taiwan and
Literature Review
Chien-Yu Lin,1 Yen-Liang Chang1,2*
Background/Purpose: Castleman’s disease (CD) is a rare and complex disease that involves the head and
neck region. In our hospital, only three cases of CD in the head and neck region have been encountered in
the past 20 years.
Methods: To establish a database of Castleman’s disease in Taiwan and to compare it to published western
studies, we collected case reports of CD in the head and neck region in Taiwan from 1992 to 2007. We used
“Castleman’s disease” and “Taiwan” as keywords to search medical journal databases. A total of 15 cases
were incorporated in our study, including three from our own hospital. These data were integrated for
studying the disease characteristics in Taiwan.
Results: Submandibular area (level I) was the most commonly involved site (5 cases, 33.3%). The ratio of
unicentric to multicentric CD and the proportion of histological classifications were similar to those in the
western studies included in our review. All of the unicentric CD treated by complete resection showed no
evidence of recurrence. Multicentric CD was present in two patients, although one died following a heart
attack. The other multicentric CD patient was treated by medication and survived for several years.
Conclusion: The features of head and neck CD in Taiwan are similar to those reported in western studies.
Although CD is not a common disease, it should be considered as a differential diagnosis in patients with
a neck mass, especially when the patient is suffering from long-term inflammation. Multicentric CD is
also likely to be initially misdiagnosed as unicentric CD. It is important to remember that all patients 
diagnosed with CD should receive a systemic survey to exclude the possibility of ignored lesions.
Key Words: Castleman’s disease, head and neck tumor
Castleman’s disease (CD) was first described by
Benjamin Castleman, who published 13 cases 
of mediastinal lymphadenopathy in 1954.1 CD
is a rare form of lymph node hyperplasia and is
also known as angiofollicular lymph node hy-
perplasia, giant lymph node hyperplasia, and an-
giofollicular lymphoid hamartoma.2 The most
prominent sites of CD are the thorax and the
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retroperitoneal area.2,3 The head and neck re-
gion is the second most common site. CD can-
not be distinguished by clinical characteristics or
image analysis, but can be proven by pathology.
Clinically, CD can be classified as unicentric or
multicentric. Unicentric CD (UCD) involves a
single node or localized group of nodes, whereas
multicentric CD (MCD) presents with poly-
lymphadenopathy and frequently multi-organ
involvement, and is associated with systemic
symptoms. However, CD can also be classified
histologically (Table 1). The most common type
of CD is the hyaline-vascular type that comprises
71–90% of all cases. The plasma-cell type accounts
for 20% of UCD and 90% of MCD.2,4 Mixed
forms of CD exist with elements of hyaline-
vascular and plasma-cell types both present. In
recent years, human herpes virus-8 (HHV-8)-
associated MCD, which is also known as plasma-
blastic MCD, has been distinguished from MCD.
This has attracted attention because of the asso-
ciation between human immunodeficiency virus
(HIV) and HHV-8.5
Materials and Methods
Online medical journal databases were utilized
for data collection. “Castleman’s disease” and
“Taiwan” were the keywords for searching 
MEDLINE, PubMed and CEPS databases. After
excluding CD from non-head and neck sites, 21
cases of head and neck CD were found. The earli-
est case report was published in 1992 and the lat-
est in 2007. Of these 21 cases, nine were excluded
from our analysis due to insufficient information
(position of lesion, disease duration and follow-
up time). In addition, three cases of CD were di-
agnosed and treated in our hospital, and these
were also included in our study. The diagnosis of
CD for all patients was verified by lymph node
biopsy. A total of 15 cases were included in our
study for further analysis.
This paper was approved for publication by
our institutional review board.
Results
Age and sex
The demographic data of all 15 patients are pre-
sented in Table 2. The male to female ratio was
approximately 1:1 (7 male and 8 female), and
their ages ranged from 9 to 80 years (median =
33 years; mean = 38.5 years).
Histological type and location
The tumor was localized unicentrically in 13
cases (86.67%) and multicentrically in only two
(13.33%). Of the 13 localized masses, 12 were
hyaline-vascular type (92.30%), one was mixed
type (7.69%), and none were plasma-cell type.
Conversely, all MCD was of the plasma-cell type.
In our UCD group, level I (5/12 case 33.3%) was
the most common site of CD. Levels II/III and
IV/V were found in two (13.3%) and four (26.6%)
cases, respectively. One case (6.6%) was reported
in the parotid area and another (6.6%) in the 
nasopharyngeal area (Table 3).
Clinical presentation
All UCD patients were asymptomatic or had symp-
toms that were caused by compression. However,
one patient suffered from constitutional symp-
toms (fever, weight loss, fatigue and sweating)
and had mixed type UCD. In contrast, the mani-
festation of MCD was primarily systemic. General
malaise was noted in both patients. One MCD
patient (case 2) presented with weight loss, dys-
pnea, anemia and thrombocytopenia. Physical
examination showed enlarged nodes in bilateral
cervical, axillary and inguinal regions. Furthermore,
chest X-ray revealed cardiomegaly with athero-
sclerotic change and bilateral perihilar interstitial
infiltration, which indicated impending cardiac
failure. Electrocardiography showed premature
atrial contractions and premature ventricular con-
tractions (PVCs). Diuretics and an antiarrhythmic
agent were prescribed for congestive heart failure
and PVC, respectively. The patient experienced sud-
den onset of PVC with progression to ventricular
fibrillation and died on the day of nodal biopsy.
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The other MCD patient (case 8) presented with
poor appetite and general weakness. Physical ex-
amination and image analysis showed spleno-
megaly, hepatomegaly and ascites. A left neck
mass (3.0 × 3.0 cm) was immediately noted. After
excision, a recurrent neck mass was noted at the
same location 1 year later. At this time, the patient
underwent excision of the mass. After 3 years, mul-
tiple left neck masses recurred as well as multiple
prevertebral and retroperitoneal lymphadenopa-
thy that were discovered following imaging.
Treatment
The treatment of all UCD patients consisted of sur-
gical excision, and no recurrence was noted after
complete resection. In contrast, one MCD patient
(case 2) underwent nodal biopsy at the area of
the left posterior cervical triangle. This patient
died from PVC on the same day of biopsy despite
intravenous lidocaine injection and vigorous car-
diopulmonary resuscitation. The other case of
MCD (case 8) underwent two nodal biopsies, and
both pathological reports revealed plasma-cell
type. Multiple lymphadenopathy was noted after
a complete imaging study. In this situation, sur-
gical excision was impossible and the patient 
received medical treatment and follow-up at the
outpatient department (Table 4).
Discussion
Hyaline-vascular CD
Hyaline-vascular CD is the most common type of
CD; it usually presents unicentrically and affects
men and women equally. The median age at pres-
entation is 40–50 years. The etiology of the dis-
ease remains unclear, but some relationship has
been reported with dysplastic follicular dendritic
cells.14 In addition, vascular proliferation in this
subtype of CD might be related to vascular en-
dothelial growth factor.15 Hyaline-vascular CD
usually appears asymptomatic, except for associ-
ated symptoms being induced by a mass effect.
In our study, most UCD patients were of the 
hyaline-vascular type and asymptomatic, except
for one who presented with mixed-type CD and
suffered from constitutional symptoms. The symp-
toms were assumed to be related to the plasma-
cell component.
Table 3. Distribution of Castleman’s disease in the
head and neck
Location Number of patients Ratio (%)
Level I 5 33.3
Level II/III 2 13.3
Level IV/V 4 26.6
Parotid 1 6.6
Nasopharynx 1 6.6
Diffuse 2 13.3
Total 15 100
Table 4. Comparison between clinical features of unicentric and multicentric Castleman’s disease
Patients UCD (n = 13) MCD (n = 2)
Age range (yr) 9–80 45–75
Mean age (yr) 44.38 60.00
Manifestation Asymptomatic Systemic symptoms such as general weakness, 
Incidentally discovered malaise, fever
Compression symptom
Histological features Hyaline-vascular type (92.3%) Plasma-cell type (100%)
Mixed type (7.7%)
Lymph node distribution Most common in level I area Diffused lymphadenopathy
Clinical course Benign Progressive
Treatment Surgical excision Medical therapy
Prognosis Excellent Guarded/poor
UCD = unicentric Castleman’s disease; MCD = multicentric Castleman’s disease.
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Histologically, hyaline-vascular CD is character-
ized by prominent proliferation of small, hyalin-
ized follicles with marked interfollicular vascular
proliferation. The follicles are round, of various
sizes, and surrounded by a cuff of small lympho-
cytes that is arranged in a concentric “onion skin”
layer with germinal centers that frequently demon-
strate atrophy with radially penetrating blood
vessels.
Our study was similar to a western study that
concluded that the hyaline-vascular type represents
76–91% of UCD. In addition, the most com-
monly involved site was level I (5 cases). Levels
II/III and IV/V were found in two and four cases,
respectively. Other locations included the parotid
area (1 case) and nasopharynx (1 case). The distri-
bution result was different from a Korean study
that showed level III to be the most common
site.16 However, both studies had limited popu-
lations, thus a larger study is needed for further
evaluation.
Surgical excision of UCD is believed to be the
treatment of choice. The number of reported cases
is limited but it appears that complete resection
is curative. The recurrent rate of UCD after com-
plete resection is very low and the prognosis is
still very good even after a second surgical inter-
vention. Radiotherapy has also been reported to
be effective in some patients with UCD and is
considered a treatment option for patients who
are poor surgical candidates or have undergone
incomplete resection.17 In our study, all UCD 
patients received complete resection as therapy,
and no tumor recurrence was noted during the
follow-up period.
Plasma-cell CD
Plasma-cell CD is more commonly multicentric
than unicentric, with only 9–24% of CD patients
presenting with localized CD.2,4 Unlike hyaline-
vascular CD, unicentric plasma-cell CD is more
likely to be associated with systemic symptoms
and abnormal laboratory findings. Approximately
50% of plasma-cell CD patients display systemic
symptoms of fever, night sweats, malaise, spleno-
megaly, anemia, cytopenia, elevated erythrocyte
sedimentation rate, hypergammaglobulinemia
and bone marrow plasmacytosis.4 Plasma-cell
CD is also considered to be a risk for POEMS
(polyneuropathy, organomegaly, endocrinopathy,
M protein and skin changes) syndrome and 
lymphoma.18
Histologically, continuous sheets of dense
plasma-cell infiltration and less vascular interfol-
licular stroma surrounding the germinal centers
were prominent features of plasma-cell CD. Other
entities involved in the differential diagnosis in-
clude B-cell lymphoma, reactive lymphadenopathy
(infection or immunodeficiency) and autoimmune
disease. A special immunohistochemical stain is
needed for differential diagnosis.
Interleukin (IL)-6 is a B-cell-stimulatory cy-
tokine that seems to be intimately linked with the
systemic manifestations of CD.19 Blockade of IL-6
signal transduction with an anti-IL-6 receptor anti-
body alleviates the systemic manifestations.20 No
IL-6 overproduction is detected in hyaline-vascular
CD. The genome of HHV-8 encodes a viral analog
to human IL-6.21 Viral IL-6 is known to have
hematopoietic and angiogenic effects, although
the exact role of viral IL-6 in the pathogenesis of
HHV-8-related diseases has yet to be investigated.
The etiology and pathogenesis of plasma-cell
CD remains to be established. It might be associ-
ated with a chronic inflammatory process, viral
infection, immunological disturbance, or neo-
plastic formation. Various studies have suggested
that it is associated with infection by Epstein–Barr
virus, toxoplasma, Mycobacterium tuberculosis, or
Kaposi’s sarcoma herpesvirus.22,23 In our study,
one mixed-type CD patient had suffered from 
tuberculosis of the spine for a long time. The
onset of CD (especially the plasma-cell form)
might have a relationship with tuberculosis.
MCD
MCD is a systemic disease that presents with 
disseminated lymphadenopathy, hepatospleno-
megaly, and constitutional symptoms. Histologi-
cally, it is similar to unicentric plasma-cell CD,
although the range of tumor extension is much
larger.
Castleman’s disease in Taiwan
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MCD and plasma-cell CD have overlapping
symptoms and pathological features; therefore,
some studies have considered that MCD might
also be associated with IL-6. MCD is associated
with a number of malignancies including Kaposi’s
sarcoma, non-Hodgkin’s lymphoma, Hodgkin’s
lymphoma and POEMS syndrome. Most patients
with MCD die of sepsis, a systemic inflammation
that leads to multi-organ failure or malignancy.
The prognosis of MCD is poor, with a median
range of survival between 14 and 30 months. In
our case series, two patients were diagnosed with
MCD. The ratio of MCD in all CD cases was
13.3%, and both MCD patients suffered from
systemic symptoms. One patient died from PVC
when nodal biopsy was performed. It is worth
mentioning that one patient was diagnosed with
plasma-cell type UCD initially and received
complete resection twice, but the tumor recurred
at the same site. In addition to the primary site,
the tumor was found in pulmonary prevertebra,
and retroperitoneal lymphadenopathy by image
analysis. In this case, MCD was the final diagno-
sis. CD can be a systemic disease and MCD is
also likely to be initially misdiagnosed as UCD.
Some case reports have shown plasma-cell CD
after a single node excision despite the fact that
the lymphadenopathy was in fact MCD, and the
disease had been misdiagnosed as the unicentric
form.
HHV-8-associated MCD
HHV-8-associated MCD is a newly established
subtype that is distinguished from MCD because
of its association with immunosuppressed indi-
viduals, especially HIV-positive patients.24 Histo-
logically, its features are similar to plasma-cell
CD, and furthermore, the plasmablastic cells are
scattered in the interfollicular area and even form
microscopic collections called microlymphomas.6
HHV-8-associated MCD presents some risk of
progression to a particular form of large B-cell
lymphoma. The prognosis of HHV-8-associated
MCD is very poor, and the estimated survival time
is only a few months. A recent study has dem-
onstrated a 15-fold increased risk of lymphoma
among HIV-positive patients with MCD, com-
pared with case-matched HIV-positive patients
without CD.25
Treatment
Unicentric CD is often successfully treated by a sin-
gle surgical resection. As a result of the dissemi-
nated nature of the lymphadenopathy in MCD,
complete surgical debulking is rarely possible.
Apart from surgery, other therapy includes cytore-
ductive chemotherapy, radiotherapy, immunomo-
dulators, monoclonal antibodies and antiviral
therapy. However, current therapies are still con-
troversial and further research is needed.
To conclude, CD is a heterogeneous and so-
phisticated disorder that might represent a con-
tinuous spectrum of disease or several different
diseases all together. The results in our study were
similar to those of western studies. The optimal
treatment of CD is complex, but UCD can be
cured by surgery alone. The heterogeneity and
rarity of MCD has confounded progress in its
management. Chemotherapy might be most 
appropriate for patients with systemic manifesta-
tions of MCD, but randomized trials are needed.
Although CD is not a common disease, it should
be considered as a possible diagnosis when the
patient complains of a neck mass, especially when
the patient is suffering from a long-term inflam-
matory course. MCD is also likely to be initially
misdiagnosed as UCD. It is important to remember
that all patients confirmed to have CD should re-
ceive further evaluation and a systemic survey to
exclude the possibility of ignored lesions.
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